How the HPV Vaccine That Saved Women Is Now Shielding Men

A shot first pitched as a defense against cervical cancer is quietly turning into a broader shield — one that now appears to protect men from certain deadly throat cancers.

When the HPV vaccine reached the market in 2006 it was aimed squarely at preventing cervical cancer in girls and women. The gamble paid off: in countries with strong uptake, cervical cancer cases have fallen by nearly 90 percent. Elimination of the disease is no longer a fantasy; it is a plausible future.

But biology does not respect the categories we assign it. The same high-risk strains of human papillomavirus that seed cervical tumors also drive oropharyngeal cancers — cancers of the throat and tonsils that have been rising fastest among men. New population-level research from the United States adds weight to a growing consensus: vaccinating boys matters.

In an observational analysis of health records for about 1.4 million people aged 9 to 45, researchers compared more than 700,000 vaccinated individuals with an age-matched unvaccinated group. They found 40 head and neck cancer cases among those who had received the HPV shot, versus 130 cases in the unvaccinated cohort — a difference approaching a 70 percent reduction. The signal was strongest for oropharyngeal squamous cell carcinoma and among younger recipients.

Kaplan-Meier curve of cumulative incidence of head and neck cancers in the HPV-vaccinated versus control cohort over 10 years.

The paper, published in The International Journal of Infectious Diseases in 2026, does not yet constitute proof of causation. But it follows a rapid policy pivot: in 2020 the US regulator expanded the vaccine's official indications to include prevention of head and neck cancers in both sexes, a move now reinforced by emerging real-world data.

Numbers help explain why this matters. Each year in the US HPV accounts for roughly 11,100 cervical cancers and about 16,000 oropharyngeal cancers — and roughly 85 percent of those throat cases occur in men. Unlike cervical disease, which can be spotted early with screening tests like the Pap smear, there is no routine screen for precancerous lesions in the throat. Prevention, therefore, becomes the primary public health tool.

HPV is surprisingly common. Most people encounter it at some point, typically without dire consequences. But a subset of high-risk strains can persist silently, sometimes for decades, quietly undermining cellular machinery until a cancer emerges years after the original infection. Transmission routes include sexual contact, and the virus reaches the throat most clearly through oral sex — and possibly through intimate contact such as kissing.

Cervical cancer mortality rates have steadily declined in the US over the past three decades and dropped sharply in the past few years.

Coverage matters. In the United States, the vaccine is recommended for young people through age 26. By 2024, 77 percent of adolescent males and 79 percent of adolescent females had received at least one dose. Yet awareness lags. A 2025 survey found that more than a third of adults were unfamiliar with HPV, and over 70 percent did not know it could cause oral cancers. Survivors who barely escaped HPV-driven tumors now say they tell every relative to get vaccinated — a simple step, they argue, that could spare years of fear and invasive treatment.

Globally, vaccination strategies remain uneven. The World Health Organization targets 90 percent vaccination of girls by age 15 but treats boys as secondary priorities where resources allow. Advocacy groups are pushing for gender-neutral vaccination policies, arguing that it makes little epidemiological sense to protect only one half of the population when both sexes face risk.

The accumulating evidence suggests that broad, gender-neutral HPV immunization could cut the burden of head and neck cancers, especially among men.

Science has long linked HPV to cervical cancer; that link brought us a vaccine that works. Newer data hint that the same tool can blunt a different, rising threat — cancers in the throat that disproportionately affect men. If a preventive injection given in adolescence can prevent cancers that show up decades later, the question becomes not whether we have the tools, but how quickly we will use them for everyone who stands to benefit.